(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 August 2011 (04.08.2011)

PCT

(10) International Publication Number
WO 2011/094489 A1

(51) International Patent Classification:
A61K 31/454 (2006.01) *A61P 1/16* (2006.01)
A61K 31/4535 (2006.01)

(21) International Application Number:
PCT/US2011/022854

(22) International Filing Date:
28 January 2011 (28.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/299,643	29 January 2010 (29.01.2010)	US
61/308,506	26 February 2010 (26.02.2010)	US
61/309,117	1 March 2010 (01.03.2010)	US
61/324,395	15 April 2010 (15.04.2010)	US

(71) Applicant *(for all designated States except US)*: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ROSARIO, Maria** [PT/US]; 6 School Street, Apt. 19, Mystic, CT 06355 (US). **CHAURET, Nathalie** [CA/CA]; 275 Armand-frappier, Laval, QC H7V 4A7 (CA). **GEORGE, Shelley** [IE/US]; 52 Wareland Road, Wellesley, MA 02481 (US). **KIEFFER, Tara, Lynn** [US/US]; 20 Abbottsford Road, Brookline, MA 02466 (US). **KOZIEL, Margaret, James** [US/US]; 198 Washington Avenue, Needham, MA 02492 (US). **NICOLAS, Olivier** [CA/CA]; 275 Armand-frappier, Laval, QC H7V 4A7 (CA). **PROULX, Louise** [CA/CA]; 275 Armand-frappier, Laval, QC H7V 4A7 (CA).

(74) Agent: **LIM, Booyong, S.**; Vertex Pharmaceuticals Incorporated, 130 Waverly Street, Cambridge, MA 02139 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/094489 A1

(54) **Title**: THERAPIES FOR TREATING HEPATITIS C VIRUS INFECTION

(57) **Abstract**: A method of improving the pharmacokinetics of VX-222 in a patient infected with HCV comprises co-administering VX-222 and VX-950 to the patient. A method of treating a patient infected with HCV comprises administering VX-222 and VX-950 to the patient, wherein VX-222 is in an amount of about 20 mg to about 400 mg, and wherein VX-950 is in an amount of about 100 mg to about 1,500 mg. A method of treating a patient infected with HCV comprises administering a therapeutically effective amount of VX-222, wherein VX- 222 is administered at an amount of about 20 mg to about 2,000 mg once a day.